Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 48Active not recruiting 31Completed 14Terminated 10Not yet recruiting 3Withdrawn 2Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 18Leukemia, Myeloid, Acute 15Breast Neoplasms 14Glioblastoma 13Colorectal Neoplasms 13Prostatic Neoplasms 11Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Lung Neoplasms 9Glioma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 7Multiple Myeloma 7Head and Neck Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Ovarian Neoplasms 5Melanoma 5Uterine Cervical Neoplasms 4Colonic Neoplasms 4Brain Neoplasms 4Solid Tumor 3Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

eltrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Leukemia, Myelomonocytic, Chronic × 1 year × Clear all
NCT06630221 2026-06-05

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Case Comprehensive Cancer Center

Phase 2 Suspended
25 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡